[BXLT] Baxalta Incorporated

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 46.16 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart BXLT

Refresh chart

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities689 M Cash From Investing Activities-547 M Cash From Operating Activities-142 M Gross Profit790 M
Net Profit272 M Operating Profit339 M Total Assets9.02 B Total Current Assets3.23 B
Total Current Liabilities1.23 B Total Debt317 M Total Liabilities2.66 B Total Revenue1.36 B
Technical Data
High 52 week46.13 Low 52 week37.99 Last close46.02 Last change0%
RSI Average true range Beta0.63 Volume
Simple moving average 20 days0% Simple moving average 50 days0% Simple moving average 200 days0.24%
Performance Data
Performance Week0% Performance Month0% Performance Quart0% Performance Half0%
Performance Year19.86% Performance Year-to-date0% Volatility daily0% Volatility weekly0%
Volatility monthly0% Volatility yearly0% Relative Volume0% Average Volume
New High New Low

News

2019-02-06 19:33:09 | Shire Acq Inv Ireland Designated Activity Co -- Moody's upgrades Shire's debt ratings to Baa2; stable outlook

2018-05-09 12:31:09 | Shire Acq Inv Ireland Designated Activity Co -- Moody's reviews Shire's Baa3 ratings for upgrade

2018-03-20 14:10:08 | Shire Acq Inv Ireland Designated Activity Co -- Moody's affirms Shire at Baa3; revises outlook to positive

2017-09-12 13:40:44 | 5 Companies Reach 52-Week Highs

2017-07-13 10:00:16 | Durham company bulks up executive suite as cancer therapy development moves forward

2017-06-12 07:37:05 | How Does Baxter Create Value for Its Shareholders?

2017-05-23 11:53:00 | Alexion: Look Out Below!

2017-01-09 11:23:00 | Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation

2017-01-06 22:05:05 | CTI Biopharma stock revived after FDA ruling, reverse stock split

2016-12-20 14:05:06 | 16 companies we lost in 2016

2016-12-16 13:04:00 | 5 Biggest Acquisitions of 2016

2016-11-01 12:22:58 | Shire slips on poor sales of haemophilia drugs

2016-11-01 08:18:44 | Shire reiterates full-year guidance after in-line Q3

2016-09-16 13:58:26 | Shire plc -- Moody's assigns Baa3 to Shire's sr. notes; stable outlook

2016-09-12 11:04:29 | After Spinning Off Hemophilia Business, What’s Next for Biogen?

2016-08-30 16:08:17 | Baxter Going Strong

2016-08-17 17:29:41 | Steve Mandel Buys Shire, Axes 6 Positions in 2nd Quarter

2016-08-10 10:12:06 | Baxter International Inc. -- Moody's rates Baxter's new notes Baa2; outlook stable

2016-08-02 09:46:33 | Shire lifts earnings and Baxalta cost saving targets

2016-08-02 07:20:44 | Shire upgrades Baxalta cost savings after Q2 earnings beat

2016-08-02 07:08:27 | Shire Says Baxalta Combination to Boost Profit; Stock Surges

2016-07-28 10:00:00 | 3 Mutual Funds Focusing on Arbitrage Profits MERFX, ARBFX

2016-07-26 20:26:10 | Dan Loeb's Third Point tells why investing is like 'Game of Thrones'

2016-07-26 20:26:10 | Dan Loeb's Third Point tells why investing is like 'Game of Thrones'

2016-07-26 09:25:01 | Baxter International BAX Q2 Earnings, Sales Top; View Up

2016-07-26 07:11:54 | Baxter Beats Earnings Estimates, Raises Full-Year Guidance

2016-06-24 18:37:58 | Steve Mandel Exits Position in Williams Companies in 1st Quarter

2016-06-21 10:00:00 | Top 3 Stocks Hedge Funds Bought in Q1, 2016

2016-06-08 15:23:43 | Pharmaceutical Stocks Hedge Funds Are Bullish on

2016-06-06 13:02:35 | Shire plc -- Moody's downgrades Baxalta to Baa3; stable outlook

2016-06-03 16:14:00 | BAXALTA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agre

2016-06-03 03:40:00 | Shire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions

2016-06-02 12:48:32 | BioMarin Withdraws Application for Kyndrisa: Stock Falls 2.5%

2016-05-31 16:19:02 | Shire’s Shareholders Approve Baxalta Merger: What’s Next?

2016-05-27 17:50:00 | TransDigm Group Set to Join the S&P 500; Helen of Troy and Brocade Communications Systems to Join S&P MidCap 400; Team and MDC Holdings to Join S&P SmallCap 600

2016-05-27 14:33:00 | 7 Stocks Seeing Big Volume -- and How to Trade Them From Here

2016-05-27 12:55:58 | BAXALTA INC Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statem

2016-05-27 11:23:00 | Shire Expects to Wrap Up Baxalta Buy on June 3

2016-05-27 10:00:00 | CORRECTING and REPLACING Baxalta Shareholders Vote to Approve Combination

2016-05-27 09:14:10 | BAXALTA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statemen

2016-05-25 06:56:03 | Kamada’s Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform

2016-05-24 20:26:00 | Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.

2016-05-24 20:00:00 | Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.

2016-05-19 07:22:06 | Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® irinotecan liposome injection Regimen in Metastatic Colorectal Cancer

2016-05-10 16:01:00 | Baxalta Declares Quarterly Dividend

2016-05-03 03:00:06 | Kamada Receives Two Milestone Payments under Strategic Agreements with Chiesi Farmaceutici and Baxalta

2016-04-29 08:54:30 | Shire jumps as Vyvanse drug helps it to beat earnings forecast

2016-04-29 08:48:22 | Shire jumps as Vyvanse drug helps it to beat earnings forecast

2016-04-29 07:12:29 | Shire earnings rise on strong Vyvanse demand

2016-04-28 08:37:49 | Baxalta posts 1Q profit